Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Hypertension. 2020 Mar 16;75(5):1279–1288. doi: 10.1161/HYPERTENSIONAHA.119.14507

Figure 5. C24:0- and C24:1-Cer prevail over C16:0-Cer in restoring flow-mediated vasodilation in ECKO-Sptlc2 MA.

Figure 5.

ECKO-Sptlc2 mice treated with C16:0-Cer, C24:0-Cer, C24:1-Cer at the doses of 3 mg/Kg/d (left panels) or 10 mg/Kg/d (right panels) i.p. for 2 consecutive days. Flow-induced vasodilation in MA from ECKO-Sptlc2 mice treated with (A) C16:0-Cer (n≥ 4mice/group); (B) C24:0-Cer (n≥4 mice/group); (C) C24:1-Cer (n≥4 mice/group). (D) Flow-induced maximum vasodilation (Emax) of MA from ECKO-Sptlc2 mice treated with two different doses of C16:0-Cer, C24:0-Cer or C24:1-Cer compared to corn oil as vehicle. (E) Scheme representing specific effects of different ceramides on flow-induced vasodilation. Data are expressed as mean ± SEM. *** p≤0.001 ECKO-Sptlc2 + corn oil vs. Sptlc2f/f + corn oil; ° p≤0.05 and °°° p≤0.001 ECKO-Sptlc2 + ceramide vs. ECKO-Sptlc2 + corn oil. Statistical significance was determined by Two-way ANOVA (A, B, C) or One-way ANOVA (D).